D
Immix Biopharma, Inc. IMMX
$2.03 -$0.065-3.10% NASDAQ
Recommendation
Prev Close
$2.10
Volume
43,007
Avg Vol (90D)
75,202
Market Cap
$58.08M
Dividend & Yield
--
52-Week Range
$1.26 - $2.71
P/E (TTM)
--
EPS (TTM)
-$0.7828
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Immix Biopharma (IMMX) to Release Earnings on Thursday
5/3/2025 - MarketBeat
Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Down 44.8% in April
5/1/2025 - MarketBeat
Favourable Signals For Immix Biopharma: Numerous Insiders Acquired Stock
4/30/2025 - Simply Wall St
Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025
4/23/2025 - GuruFocus
Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO ...
4/23/2025 - GuruFocus
Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025
4/23/2025 - Globe Newswire
Immix Biopharma (NASDAQ:IMMX) Issues Quarterly Earnings Results, Beats Estimates By $0.09 EPS
3/27/2025 - MarketBeat
Immix Biopharma (NASDAQ:IMMX) Announces Earnings Results, Beats Estimates By $0.09 EPS
3/26/2025 - Ticker Report
Immix Biopharma (IMMX) Projected to Post Quarterly Earnings on Thursday
3/20/2025 - MarketBeat
Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?
3/8/2025 - Simply Wall St
Immix Biopharma (NASDAQ:IMMX) Receives Buy Rating from HC Wainwright
2/13/2025 - Ticker Report
HC Wainwright Reiterates "Buy" Rating for Immix Biopharma (NASDAQ:IMMX)
2/10/2025 - MarketBeat
Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ...
2/10/2025 - GuruFocus
Immix Biopharma receives FDA RMAT designation for NCX-201 in r/r AL Amyloidosis
2/10/2025 - The Fly
Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis
2/10/2025 - Globe Newswire
Short Interest in Immix Biopharma, Inc. (NASDAQ:IMMX) Declines By 11.0%
1/20/2025 - MarketBeat
Geode Capital Management LLC Has $224,000 Stake in Immix Biopharma, Inc. (NASDAQ:IMMX)
1/14/2025 - Ticker Report
Favourable Signals For Immix Biopharma: Numerous Insiders Acquired Stock
1/13/2025 - Simply Wall St
FY2024 EPS Forecast for Immix Biopharma Decreased by Analyst
1/9/2025 - MarketBeat
Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T
1/7/2025 - GuruFocus
Immix Biopharma accelerates enrollment in U.S. AL amyloidosis trial of NXC-201
1/7/2025 - The Fly
Immix Biopharma Accelerates Enrollment in U.S. AL Amyloidosis Trial of NXC-201 CAR-T
1/7/2025 - Globe Newswire
Immix Biopharma (NASDAQ:IMMX) Given "Buy" Rating at HC Wainwright
1/7/2025 - Ticker Report
Immix Biopharma (NASDAQ:IMMX) Given "Buy" Rating at HC Wainwright
1/6/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$22.64M
EBIT (TTM)
-$22.67M
Net Income (TTM)
-$21.61M
Balance Sheet
Total Assets (Q)
$22.95M
Total Debt (Q)
$1.07M
Total Liabilities (Q)
$9.70M
Book Value Per Share (Q)
$0.4812
Cash Flow
Cash from Operations (TTM)
-$14.60M
Cash from Investing (TTM)
-$1.18M
Cash from Financing (TTM)
$15.95M
Net Change in Cash (TTM)
$172.10K
Filings
Filing Date
Tuesday, March 25, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
0.57
7-Day Total Return
16.00%
30-Day Total Return
12.78%
60-Day Total Return
0.50%
90-Day Total Return
-6.45%
Year to Date Total Return
-7.73%
1-Year Total Return
-13.62%
2-Year Total Return
-26.98%
3-Year Total Return
42.96%
5-Year Total Return
--
52-week Low
Oct 04, 2024 - $1.26
52-week High
Dec 06, 2024 - $2.71
Valuation
Market Cap
$58.08M - Micro Cap
Enterprise Value
$41.47M
Price/Sales (TTM)
--
Price/Book (Q)
4.35
Dividends and Shares
Shares Outstanding
29.56M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.immixbio.com
Phone Number
310 651 8041
Address
11400 West Olympic Boulevard
Los Angeles, CA 90064
Country
United States
Year Founded
2012
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in... more
NASDAQ 05/05/2025 4:00PM Eastern Quotes delayed